Literature DB >> 22693264

Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client.

Andrew P Trotta1, Eleanor F Need, Lisa M Butler, Luke A Selth, Melissa A O'Loughlin, Gerhard A Coetzee, Wayne D Tilley, Grant Buchanan.   

Abstract

Ligand-dependent activity of steroid receptors is affected by tetratricopeptide repeat (TPR)-containing co-chaperones, such as small glutamine-rich tetratricopeptide repeat-containing alpha (SGTA). However, the precise mechanisms by which the predominantly cytoplasmic TPR proteins affect downstream transcriptional outcomes of steroid signaling remain unclear. In this study, we assessed how SGTA affects ligand sensitivity and action of the androgen receptor (AR) using a transactivation profiling approach. Deletion mapping coupled with structural prediction, transcriptional assays, and in vivo regulation of AR-responsive promoters were used to assess the role of SGTA domains in AR responses. At subsaturating ligand concentrations of ≤ 0.1 nM 5α-dihydrotestosterone, SGTA overexpression constricted AR activity by an average of 32% (P<0.002) across the majority of androgen-responsive loci tested, as well as on endogenous promoters in vivo. The strength of the SGTA effect was associated with the presence or absence of bioinformatically predicated transcription factor motifs at each site. Homodimerizaion of SGTA, which is thought to be necessary for chaperone complex formation, was found to be dependent on the structural integrity of amino acids 1-80, and a core evolutionary conserved peptide within this region (amino acids 21-40) necessary for an effect of SGTA on the activity of both exogenous and endogenous AR. This study provides new insights into the subdomain structure of SGTA and how SGTA acts as a regulator of AR ligand sensitivity. A change in AR:SGTA ratio will impact the cellular and molecular response of prostate cancer cells to maintain androgenic signals, which may influence tumor progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22693264     DOI: 10.1530/JME-11-0152

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  10 in total

1.  The cochaperone SGTA (small glutamine-rich tetratricopeptide repeat-containing protein alpha) demonstrates regulatory specificity for the androgen, glucocorticoid, and progesterone receptors.

Authors:  Atanu Paul; Yenni A Garcia; Bettina Zierer; Chaitanya Patwardhan; Omar Gutierrez; Zacariah Hildenbrand; Diondra C Harris; Heather A Balsiger; Jeffrey C Sivils; Jill L Johnson; Johannes Buchner; Ahmed Chadli; Marc B Cox
Journal:  J Biol Chem       Date:  2014-04-21       Impact factor: 5.157

Review 2.  New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.

Authors:  Margaret M Centenera; Luke A Selth; Esmaeil Ebrahimie; Lisa M Butler; Wayne D Tilley
Journal:  Cold Spring Harb Perspect Med       Date:  2018-12-03       Impact factor: 6.915

3.  Expression and clinical role of small glutamine-rich tetratricopeptide repeat (TPR)-containing protein alpha (SGTA) as a novel cell cycle protein in NSCLC.

Authors:  Qun Xue; Liting Lv; Chunhua Wan; Buyou Chen; Mei Li; Tingting Ni; Yifei Liu; Yanhua Liu; Xia Cong; Yiqun Zhou; Runzhou Ni; Guoxin Mao
Journal:  J Cancer Res Clin Oncol       Date:  2013-07-16       Impact factor: 4.553

4.  Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.

Authors:  Nada Lallous; Eric Leblanc; Ravi S N Munuganti; Mohamed D H Hassona; Nader Al Nakouzi; Shannon Awrey; Helene Morin; Mani Roshan-Moniri; Kriti Singh; Sam Lawn; Takeshi Yamazaki; Hans H Adomat; Christophe Andre; Mads Daugaard; Robert N Young; Emma S Tomlinson Guns; Paul S Rennie; Artem Cherkasov
Journal:  Mol Cancer Ther       Date:  2016-10-07       Impact factor: 6.261

5.  Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome.

Authors:  Damien A Leach; Eleanor F Need; Roxanne Toivanen; Andrew P Trotta; Helen M Palethorpe; Helen M Palenthorpe; David J Tamblyn; Tina Kopsaftis; Georgina M England; Eric Smith; Paul A Drew; Carole B Pinnock; Peng Lee; Jeff Holst; Gail P Risbridger; Samarth Chopra; Donald B DeFranco; Renea A Taylor; Grant Buchanan
Journal:  Oncotarget       Date:  2015-06-30

6.  Small Glutamine-Rich Tetratricopeptide Repeat-Containing Protein Alpha (SGTA) Ablation Limits Offspring Viability and Growth in Mice.

Authors:  Lisa K Philp; Tanya K Day; Miriam S Butler; Geraldine Laven-Law; Shalini Jindal; Theresa E Hickey; Howard I Scher; Lisa M Butler; Wayne D Tilley
Journal:  Sci Rep       Date:  2016-06-30       Impact factor: 4.379

7.  Canine REIC/Dkk-3 interacts with SGTA and restores androgen receptor signalling in androgen-independent prostate cancer cell lines.

Authors:  Yuiko Kato; Kazuhiko Ochiai; Shota Kawakami; Nobuhiro Nakao; Daigo Azakami; Makoto Bonkobara; Masaki Michishita; Masami Morimatsu; Masami Watanabe; Toshinori Omi
Journal:  BMC Vet Res       Date:  2017-06-09       Impact factor: 2.741

Review 8.  The roles of cytosolic quality control proteins, SGTA and the BAG6 complex, in disease.

Authors:  Rashi Benarroch; Jennifer M Austin; Fahmeda Ahmed; Rivka L Isaacson
Journal:  Adv Protein Chem Struct Biol       Date:  2018-12-18       Impact factor: 3.507

9.  Tumor suppressor REIC/DKK-3 and co-chaperone SGTA: Their interaction and roles in the androgen sensitivity.

Authors:  Kazuhiko Ochiai; Masami Morimatsu; Yuiko Kato; Toshina Ishiguro-Oonuma; Chihiro Udagawa; Oumaporn Rungsuriyawiboon; Daigo Azakami; Masaki Michishita; Yuichi Ariyoshi; Hideo Ueki; Yasutomo Nasu; Hiromi Kumon; Masami Watanabe; Toshinori Omi
Journal:  Oncotarget       Date:  2016-01-19

Review 10.  SGTA: a new player in the molecular co-chaperone game.

Authors:  Lisa K Philp; Miriam S Butler; Theresa E Hickey; Lisa M Butler; Wayne D Tilley; Tanya K Day
Journal:  Horm Cancer       Date:  2013-07-02       Impact factor: 3.869

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.